by mfenimore | Nov 28, 2023 | Uncategorized
Multiple myeloma is the second-most-common hematologic malignancy in the United States with approximately 34,470 new cases diagnosed in the United States in 2022. Although multiple myeloma is an incurable disease, numerous active agents are available that, when used...
by mfenimore | Nov 28, 2023 | Uncategorized
This educational program focuses on the recognition, diagnosis, and management of patients with thyroid eye disease, the majority of whom remain undiagnosed and unaware of treatment options. The program combines flexible, self-directed learning, live group...
by mfenimore | Nov 28, 2023 | Uncategorized
As a result of the COVID-19 pandemic, we have learned valuable lessons pertinent to MS care. This includes knowledge about COVID-19 severity and infection risk (especially as it relates to DMT selection), a much greater understanding of how DMTs affect SARS-CoV-2...
by mfenimore | Nov 28, 2023 | Uncategorized
Often seen in Guillain–Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), arise as a consequence of immune system involvement and can have myriad health consequences. Both CIDP and MMN are...
by Stefan Ravello | Nov 28, 2023 | Uncategorized
Spinal muscular atrophy (SMA) can be a debilitating condition causing immobility, respiratory difficulties, and reduced lifespan. But with the advent of new disease-modifying therapies, the prognosis for patients with SMA has been completely altered. These treatments...
